Suppr超能文献

葡萄牙炎症性肠病的疾病负担和疾病成本

Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal.

作者信息

Magro Fernando, Portela Francisco, Lago Paula, Chagas Cristina, Moreira Francisco, Pereira Fábio, Rodrigues Bernardo, Pedrosa Hugo, Correia Luis

机构信息

Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal.

IBD Portuguese Group (GEDII), Porto, Portugal.

出版信息

GE Port J Gastroenterol. 2022 Jun 15;30(4):283-292. doi: 10.1159/000525206. eCollection 2023 Aug.

Abstract

BACKGROUND

Inflammatory bowel diseases' (IBD) increasing incidence and prevalence place a heavy health and economic burden on society.

OBJECTIVES

This study assesses the burden and cost of IBD in Portugal to support the definition of health policies, resource allocation, and patient care.

METHODS

The burden of disease was expressed using disability-adjusted life years (DALY). Costs were estimated considering the societal perspective, using a prevalence-based model and prices established by law. An expert panel composed of 5 expert Portuguese gastroenterologists and a patient-reported study were conducted to support the cost analysis and fill in information gaps.

RESULTS

In Portugal, with a prevalence of 24,069 IBD patients and an incidence of 15/100,000, the burden of disease was estimated at 6,067 DALYs: 507 resulting from premature deaths and 5,560 from disability. Total cost was estimated at EUR 146 million per year, with direct costs representing 59%. Average yearly cost per IBD patient is EUR 6,075, where 60% is related to Crohn's disease and 40% to ulcerative colitis (UC).

CONCLUSION

This study estimates the annual health burden and cost of IBD in Portugal, thus generating information with the intent to raise awareness of the need to advance health policies as well as better clinical and economic decisions in this pathology.

摘要

背景

炎症性肠病(IBD)发病率和患病率的不断上升给社会带来了沉重的健康和经济负担。

目的

本研究评估葡萄牙IBD的负担和成本,以支持卫生政策的制定、资源分配和患者护理。

方法

使用伤残调整生命年(DALY)来表示疾病负担。从社会角度出发,采用基于患病率的模型和法定价格估算成本。由5名葡萄牙胃肠病学专家组成的专家小组和一项患者报告研究,以支持成本分析并填补信息空白。

结果

在葡萄牙,IBD患者患病率为24,069例,发病率为15/100,000,疾病负担估计为6,067个DALY:507个由过早死亡导致,5,560个由残疾导致。每年总成本估计为1.46亿欧元,直接成本占59%。每名IBD患者的平均年度成本为6,075欧元,其中60%与克罗恩病相关,40%与溃疡性结肠炎(UC)相关。

结论

本研究估计了葡萄牙IBD的年度健康负担和成本,从而产生相关信息,旨在提高人们对推进卫生政策以及针对该疾病做出更好的临床和经济决策必要性的认识。

相似文献

1
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal.
GE Port J Gastroenterol. 2022 Jun 15;30(4):283-292. doi: 10.1159/000525206. eCollection 2023 Aug.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2.
3
The cost of illness analysis of inflammatory bowel disease.
BMC Gastroenterol. 2023 Jan 19;23(1):21. doi: 10.1186/s12876-023-02648-z.
4
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
5
Haemophilia A: health and economic burden of a rare disease in Portugal.
Orphanet J Rare Dis. 2019 Sep 4;14(1):211. doi: 10.1186/s13023-019-1175-5.
6
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness.
Pharmacoeconomics. 2021 May;39(5):579-587. doi: 10.1007/s40273-020-00993-5. Epub 2021 Jan 31.
7
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Lancet Gastroenterol Hepatol. 2020 May;5(5):454-464. doi: 10.1016/S2468-1253(20)30012-1. Epub 2020 Feb 13.
8
[ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)].
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2020 Oct;28(Special Issue):1137-1145. doi: 10.32687/0869-866X-2020-28-s2-1137-1145.
9
Costs of inflammatory bowel disease in Germany.
Pharmacoeconomics. 2006;24(8):797-814. doi: 10.2165/00019053-200624080-00006.
10

引用本文的文献

2
Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial.
Therap Adv Gastroenterol. 2025 Mar 19;18:17562848251318032. doi: 10.1177/17562848251318032. eCollection 2025.
4
Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal.
Pharmacoecon Open. 2025 May;9(3):423-431. doi: 10.1007/s41669-024-00552-0. Epub 2025 Feb 11.

本文引用的文献

1
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180.
2
Haemophilia A: health and economic burden of a rare disease in Portugal.
Orphanet J Rare Dis. 2019 Sep 4;14(1):211. doi: 10.1186/s13023-019-1175-5.
3
What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale.
Therap Adv Gastroenterol. 2019 Aug 21;12:1756284819860044. doi: 10.1177/1756284819860044. eCollection 2019.
5
Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years.
Dig Liver Dis. 2019 Jul;51(7):952-960. doi: 10.1016/j.dld.2019.01.016. Epub 2019 Feb 6.
7
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
9
Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China.
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):307-316. doi: 10.1016/S2468-1253(16)30077-2. Epub 2016 Nov 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验